14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
SRRK vs ELVN: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Enliven Therapeutics, Inc. (ELVN) is the stronger overall head-to-head candidate over Scholar Rock Holding Corporation (SRRK) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). SRRK carries a Unified Composite Score of 55.1/100 (HOLD) at $43.21 (N/M Forward P/E, -71732.3% operating margin), whereas ELVN carries 36.2/100 (SELL) at $47.54 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While SRRK currently prints a higher short-term Unified Composite Score (55.1/100 HOLD vs. ELVN 36.2/100 SELL), ELVN captures the overall institutional head-to-head verdict (5–2 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -71732.3% operating margin) and revenue trajectory (+0.0% vs. -100.0% YoY).
Technical & Structure Timing Caution: SRRK is currently in a Breakdown options structure phase (RSI 45.4); meanwhile ELVN trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 53.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SRRK vs ELVN. Trailing 12-month operating profitability (SRRK -71732.3% vs ELVN 0.0%) and valuation multiples (SRRK N/M vs ELVN N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $3.6B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ SRRK vs ELVN Key Questions & Quantitative Answers
As of Nov 16, 2026, Enliven Therapeutics, Inc. (ELVN) is the stronger overall head-to-head candidate over Scholar Rock Holding Corporation (SRRK) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). SRRK carries a Unified Composite Score of 55.1/100 (HOLD) at $43.21 (N/M Forward P/E, -71732.3% operating margin), whereas ELVN carries 36.2/100 (SELL) at $47.54 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While SRRK currently prints a higher short-term Unified Composite Score (55.1/100 HOLD vs. ELVN 36.2/100 SELL), ELVN captures the overall institutional head-to-head verdict (5–2 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -71732.3% operating margin) and revenue trajectory (+0.0% vs. -100.0% YoY). Technical & Structure Timing Caution: SRRK is currently in a Breakdown options structure phase (RSI 45.4); meanwhile ELVN trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 53.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
SRRK leads the Growth & Scale pillar: SRRK posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on $570,000 TTM revenue (N/A gross margin, -71732.3% operating margin), compared with ELVN at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, SRRK generates $570,000 in USD-normalized revenue versus N/A for ELVN. In operating R&D and SG&A reinvestment, SRRK deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ELVN.
SRRK and ELVN trade at balanced relative valuation multiples. SRRK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ELVN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SRRK (-200.0% ROE) versus ELVN (-16.8% ROE) capital efficiency.
In options market volatility and institutional positioning, SRRK carries 58.5% implied volatility (7th %ile, Compressed (<25th %ile)), a 0.53x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.02β · 61% Vol realized risk). By comparison, ELVN carries 46.9% implied volatility (5th %ile, Compressed (<25th %ile)), a 1.67x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.96β · 60% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.